Pharmacotherapy for liposarcoma: current and emerging synthetic treatments

Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15–20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable chemosensitivity according to subtype. Decisions regarding management should be made on...

Full description

Saved in:
Bibliographic Details
Published inFuture oncology (London, England) Vol. 17; no. 20; pp. 2659 - 2670
Main Authors Chamberlain, Florence, Benson, Charlotte, Thway, Khin, Huang, Paul, Jones, Robin L, Gennatas, Spyridon
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.07.2021
Subjects
liposarcomas
novel therapeutic agents
radiotherapy
systemic chemotherapy
targeted therapies
radiotherapy
systemic chemotherapy
liposarcomas
targeted therapies
novel therapeutic agents
Online AccessGet full text

Cover

More Information
Summary:Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15–20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable chemosensitivity according to subtype. Decisions regarding management should be made on an individual basis, but surgery for localized disease and systemic chemotherapy remain the mainstay of treatment. Currently, only doxorubicin and trabectedin have robust Phase III data to support their use in the management of advanced liposarcoma. However, in the subgroup analysis of a Phase III trial comparing eribulin with dacarbazine, there was a greater than 7-month improvement in median overall survival in those treated with eribulin. There are also promising results from emerging studies in novel and targeted agents for the treatment of liposarcoma.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2020-1092